Push Through, page-6

Good post Dave. I agree with your points but would suggest that RAP has not yet reached the point of having a trial (with money although I suspect it is minimal) with a major pharma. This puts MEB a little ahead don't you think? If the medication response tool works and it can be packaged with Abilify, it would give Otsuka a major advantage in an enormous market. I understand why they would be keen.
As an aside, I believe detecting response to treatment is the potential company maker here, not so much the diagnosis which depends on so many variables and uncertainties.